SCHEMBL19786145

SCHEMBL19786145

[O-][S+](C/C=C/SSCc1ccccc1)Cc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.34
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189909 1.00 MAOB (0.34) MAOBCTSLCTSB
SCHEMBL23855349 1.00 MAOB (0.34) MAOBCTSLCTSB
SCHEMBL19785874 0.92 CTSB (0.32) CTSB
SCHEMBL23855344 0.92 CTSB (0.32) CTSB
SCHEMBL19786101 0.92 CTSB (0.32) CTSB
SCHEMBL12362843 0.92 BCHE (0.38)
SCHEMBL21189910 0.88 LTA4H (0.41) CTSB
SCHEMBL21190015 0.88 LTA4H (0.41) CTSB
SCHEMBL2258867 0.88 LTA4H (0.41) CTSB
SCHEMBL2258863 0.88 LTA4H (0.41) CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-01-25 US disclosed
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-01-25 US disclosed
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2021-09-30 US disclosed
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2021-09-30 US disclosed
WO-2019143143-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROBLASTOMA OR RHEUMATOID ARTHRITIS 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
WO-2019143142-A1 NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
WO-2018012947-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT 숙명여자대학교 산학협력단 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient HDAC1, HDAC2, HDAC11 MAOB 1186/4885CTSL 2478/4885CTSB 1121/4885
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT HDAC1, HDAC2, HDAC11 MAOB 1583/4885CTSL 2473/4885CTSB 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.